Halozyme Reports Fourth Quarter And Full-Year 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Halozyme Reports Fourth Quarter And Full-Year 2017 Results
February 21, 2018 8:42 AM EST
BMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $18.00) while maintaining a Market Perform rating.
Analyst Do Kim said they believe ENHANZE continues to provide a strong valuation floor with Janssen conducting six studies. However, PEGPH20 Phase III interim data in 4Q18 remains a key risk.
...
More
February 21, 2018 6:55 AM EST
Deutsche Bank raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $24.00 (from $21.00) while maintaining a Buy rating following the company's 4Q earnings report. Results were in line with our expectations given the preliminary announcement of results earlier this year. +24.6% y/y royalty... More
February 20, 2018 4:07 PM EST
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.85, $0.13 better than the analyst estimate of $0.72. Revenue for the quarter came in at $189.6 million versus the consensus estimate of $165.19 million.
Financial Outlook for 2018
Halozyme reiterated its financial guidance of:
Net revenue of $115 million to $125...
More
